10-Q: iTeos Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

iTeos Therapeutics announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and providing an update on its financial position.

Summary

• iTeos Therapeutics reported a net loss of $34.6 million for the three months ended March 31, 2025, compared to a net loss of $38.2 million for the same period in 2024.
• Research and development expenses decreased to $29.0 million from $34.5 million year-over-year, primarily due to varying phasing of belrestotug studies and discontinuation of the inupadenant program.
• General and administrative expenses decreased to $11.0 million from $12.7 million year-over-year, mainly due to lower stock-based compensation and professional fees.
• The company's cash and cash equivalents totaled $156.5 million, and available-for-sale securities amounted to $467.7 million as of March 31, 2025.
• iTeos believes its existing cash and investments will fund operating expenses and capital expenditure requirements through 2027.
• The company is advancing its clinical programs, including belrestotug (Phase 3 and Phase 2 trials), EOS-984 (Phase 1 trial), and EOS-215 (Phase 1 trial).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there are positive signs such as the decrease in net loss, the strong cash position, and the progress in clinical programs. However, the risks associated with drug development and the competitive landscape remain.

Positives

• The net loss decreased by $3.6 million compared to the same period last year.
• Research and development expenses decreased, indicating potential efficiency in resource allocation.
• The company has a strong cash position, expected to fund operations through 2027.
• The GALAXIES Lung-301 trial triggered a $35 million milestone payment from GSK.
• The company observed a clinically meaningful objective response rate across each dostarlimab with belrestotug dosing cohort in the GALAXIES Lung-201 study.

Negatives

• The company continues to operate at a loss, with a net loss of $34.6 million for the quarter.
• The company discontinued the inupadenant program.

Risks

• The company's success depends on the outcome of clinical trials, which are inherently uncertain.
• The company faces competition from other biopharmaceutical companies.
• The company relies on third parties for manufacturing and clinical trials.
• The company may require additional financing to achieve its goals.
• The company is subject to regulatory risks and potential product liability claims.

Future Outlook

iTeos expects its existing cash and cash equivalents and available-for-sale securities will enable it to fund its operating expenses and capital expenditure requirements through 2027.

Industry Context

iTeos Therapeutics operates in the competitive immuno-oncology field, facing competition from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide. The company's focus on novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer aligns with the broader industry trend of developing innovative cancer therapies.

Comparison to Industry Standards

• It is difficult to compare iTeos's results directly to industry standards without specific benchmarks for clinical-stage immuno-oncology companies.
• Comparable companies in the space include Arcus Biosciences, Compugen, and Immatics, but their specific financial situations and clinical programs vary significantly.
• The $35 million milestone payment from GSK is a positive indicator, but the overall financial performance reflects the high costs and risks associated with drug development.
• The company's cash runway through 2027 is a positive sign, but it will need to continue to make progress in its clinical programs to maintain investor confidence.

Related Party Transactions

• Boxer Capital is considered a related party to the Company due to its Chief Executive Officer serving as a member of the Company's Board of Directors.
• The Company issued 1,142,857 shares of its common stock to Boxer Capital for total proceeds of $ 20.0 million pursuant to the SPA dated May 10, 2024.
• Boxer Capital's Chief Executive Officer subsequently resigned from the Company's Board of Directors in October 2024.
• RA Capital has historically been a related party to the Company due to its partner serving on the Company's Board of Directors and its beneficial ownership of the Company which exceeded 10 %.
• RA Capital's partner resigned from the Company's Board of Directors effective December 5, 2023.
• The Company issued to RA Capital a pre-funded warrant to purchase 5,714,285 shares of its common stock for total proceeds of $ 100.0 million pursuant to the SPA dated May 10, 2024.
• On May 14, 2024, RA Capital exchanged 900,000 shares of the Company's common stock for a pre-funded warrant to purchase up to 900,000 shares of the Company's common stock.
• Upon the execution of the Exchange Agreement, RA Capital's beneficial ownership fell below the 10 % principal owner threshold per ASC 850, Related Party Transactions .

Stakeholder Impact

• Shareholders: The report provides information on the company's financial performance and progress in its clinical programs, which may influence investment decisions.
• Employees: The company's ability to fund operations through 2027 provides job security and opportunities for growth.
• Patients: The company's clinical programs offer potential new treatment options for cancer.
• Partners: The report provides updates on the company's collaborations, including the GSK Collaboration Agreement.
• Creditors: The company's strong cash position reduces the risk of default.

Next Steps

• Continue clinical trials for belrestotug, EOS-984, and EOS-215.
• Pursue regulatory approvals for product candidates that successfully complete clinical trials.
• Continue research and development efforts to identify and develop additional product candidates.
• Manage expenses and maintain a strong financial position.

Key Dates

Keywords

belrestotug, EOS-984, EOS-215, clinical trials, immuno-oncology, GSK, TIGIT, ENT1, TREM2, financial results, iTeos Therapeutics